Mabqi is focused on the discovery and development of next-generation innovative antibodies and functional targeted therapies.
We leverage our LiteMab© Antibody Discovery Studio to tackle both conventional and complex targets, explore next-generation antibody-based therapies.
Mabqi believes in teamwork and open innovation to bring new clinical options to patients.
Mabqi’s LiteMab© Antibody Discovery Studio is ideally suited for conventional and hard-to-drug targets such as transmembrane proteins (GPCRs), ion channels, soluble proteins, peptides and many more.
The core technology is built on a suite of fully human synthetic antibody libraries, combined with AI-powered phage and yeast display technologies.
Our state-of-the-art display platforms expedite antibody discovery workflows by enabling high-throughput antibody selection, screening, and hit identification through rigorous functional validation of fully human antibody candidates.
LiteMab Discovery Studio is designed to enable the discovery of targeted therapeutics such as tumor selective binders, Antibody drug conjugates (ADC), bispecifics, TCE, multispecific antibodies.
Mabqi is building a robust pipeline of innovative targeted therapies in oncology, powered by our proprietary integrated discovery studio.
Our approach has generated a
pipeline of highly differentiated candidates with the potential to become
first- or best-in-class therapies.
